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Abstract 
Glioblastoma (GBM) is the most frequent and aggressive primary brain 
tumour in adults. Standard treatments for GBM patients consist of tumour 
resection, radiotherapy (RT) and chemotherapy with alkylating agent 
Temozolomide (TMZ). However, despite advances in surgical and 
medical treatment, prognosis for GBM patients remains dismal, with a 
median survival of 14–15 months. A small population of cancer stem 
cells (glioblastoma stem cells, GSCs), that retains stem cell properties 
including self-renewal and multipotency, has been implicated as 
responsible for the frequent relapse of glioblastoma and its resistance to 
conventional therapeutic. Thus, the identification of new molecules that 
can specifically target these GSCs is a fundamental challenge for the 
development of effective glioma therapies.  
In this study, we developed a differential whole cell-SELEX, an in 
vitro evolution-based approach, which allowed us to generate RNA-
ligands with high affinity and specificity for GSCs, named aptamers. 
These nucleic acids were obtained by means the iterative evolution of a 
random pool of sequences using human primary GSCs as target.    
The obtained aptamer, 40L had been proved to be selective for GSCs 
distinguishing them from tumor differentiated cells, obtained from the 
stem cells induced to differentiate. Moreover, 40L revealed to be 
functionally active on target cells and able to inhibit stemness, cell growth 
and migration in vitro as well as in vivo.  
In conclusion, our results indicate that 40L and its short form A40s can 
selectively target GSCs and, given the crucial role of these cells in GBM 
recurrence and multi-drug resistance, 40L and A40s represent innovative 
drug candidates with a great potential in the GBM treatment.   
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1. Background 
 
1.1. Central Nervous System and its tumours  
 
The Nervous System consists of all the nerve cells of our body which 
enable us to communicate with the outside world. The nervous system 
allows us to receive information through our senses, it is able to processes 
it and to trigger a reaction to external stimuli, such as making your 
muscles move or causing you to feel pain. Also, metabolic processes are 
controlled by the nervous system. 
Basic working units of nervous system are specific nerve cells, also called 
neurons. The brain alone has about 100 billion neurons in it. Neuron 
made up of a cell body and various extensions. Dendrites are the shorter 
extensions, they extend from the neuron cell body and they receive 
signals from, for example, other neurons and transmit them on to the cell 
body which contains the nucleus and cytoplasm. The signals are then 
transmitted on via a long extension, called axon, which can be long up to 
one meter and often gives rise to many smaller branches before ending at 
nerve terminals. Synapses are the contact points where one neuron 
communicates with another. 
Due to their location in the body, we can distinguish two different 
nervous systems, one called the central nervous system and one the 
peripheral nervous system. The central nervous system (CNS) includes 
the nerves in the brain and spinal cord. All of the other nerves in the body 
are part of the peripheral nervous system (PNS). 
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1.1.1. World Health Organization Classification of Tumours of the 
Central Nervous System 
 
 
A classification and grading concerning human tumours that is recognised 
and used worldwide is still today an important aim to reach, considering 
that, studies and clinical trials could not cross national and institutional 
boundaries without clear diagnostic criteria. 
In this respect, the World Health Organization (WHO) is drawing up 
international classifications of human tumours from 1957 until now. 
Zülch published in 1979 the first edition regarding the histological typing 
of cancers of the nervous system. Thanks to contributions made by the 
immunohistochemistry introduction into diagnostic pathology, a second 
edition was edited by Kleihues et al1. in 1993. In the year 2000 Kleihues 
and Cavenee, defined brain tumours including genetic profiles as 
supplementary aid2. 
In 2016, WHO gives form to a new way to define CNS tumours in the 
molecular era, classifying them, for the first time, using molecular 
parameters in addition to histology3. Until this version the classification 
of brain tumours was mainly based on histogenesis, classifying the 
tumours according to their microscopic similarities with various putative 
cells of origin and their supposed grades of differentiation.  
As shown in Table 1, following the 2016 World Health Organization 
Classification of Tumours of the Central Nervous System, diagnosis of 
these tumours is made up of a histopathological name followed by a 
comma and the genetic features as adjectives, such as “Anaplastic 
Astrocytoma, IDH-mutant”. For those tumours which have more than one 
genetic determinant, all the molecular features have to be included in the 
name (e.g. Anaplastic Oligodendroglioma, IDH-mutant and 1p/19q-
codeleted). The term “wildtype” is used for those tumours that luck a 
genetic mutation (e.g. Diffuse Astrocytoma, IDH-wildtype), instead the 
term “positive” can be used if a specific genetic alteration is present (e.g. 
Ependymoma, RELA fusion–positive). Finally, for some tumour types is 
possible the diagnostic designation “not otherwise specified” (NOS) for 
those sites which do not have any access to molecular diagnostic testing.  
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Table 1. Continue 
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Table 1. WHO classification of tumours of the CNS. This reference classification is 
used worldwide as an indispensable guide, providing an international standard for 
oncologists and pathologists.  
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Table 2. Grading of selected CNS tumours according to the 2016 CNS WHO. A 
synthesized classification of select of central nervous system tumours is shown. 
 
 
For concerning grades, as in the past, they are written in Roman numerals 
(e.g., I, II, III and IV; not 1, 2, 3 and 4) (Table 2), considering grade I 
tumours as the least aggressive, while grade IV as the most aggressive 
ones. Multiform Glioblastoma are Grade IV tumours (Table 3). 
 
 
7 
 
 Table 3. WHO Grading System of gliomas. Grading System of gliomas defines 
progressive malignancy of gliomas. This more accurately predicts outcomes, considering 
hypercellularity, mitosis rates, presence of necrosis, and vascular proliferation. Picture 
source: http://www.abta.org/brain-tumor-information/tumor-grade/ 
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2. Glioblastoma 
 
Glioblastoma (formerly glioblastoma multiforme; GBM) is the most 
aggressive form of glioma and corresponds to grade IV based on WHO 
Classification3. About 90% of GBM cases grow de novo from glial cells, 
as primary tumours, instead the remaining percentage can be attributed to 
secondary cancers, caused by low-grade tumours progression (diffuse or 
anaplastic astrocytomas). Glioblastoma multiforme especially the primary 
form, grows very fast, within 3 months, and has a very high rate of 
recurrence4. Surgery is among the first GBM treatments. The first 
operation on a patient suffering from this disease was conducted in 
Vienna in 1904. Given the high capacity to invade normal brain tissue, 
GBM is still particularly difficult to be completely surgically removed.  
Furthermore, the surgery is often limited by the tumour location and by 
the patient ability to tolerate it. Despite the high invasiveness GBM rarely 
metastasizes beyond the brain.  
 
 
2.1. Epidemiology 
 
2.1.1. Incidence, risk factors and survival 
 
Glioblastoma Multiforme is a rare tumor and it is the most common 
astrocytic tumour. In Europe, about 27,000 new cases of malignant 
astrocytic tumours are diagnosed per year with an annual incidence rate, 
for the period 2000-2007, of 5 per 100,000 . GBM represents more than 
50% of astrocytic tumours5 and it constitutes around the 25% of all the 
malignant cancers concerning the central nervous system. In Italy they are 
recorded around 7.000 new cases every year.  
GBM does not have an identifiable cause, generally it occurs 
spontaneously. Despite this, certain factors have been linked to an 
increased risk of developing the disease:  
 
 Age- The risk that GBM can arise increases with age, although it can 
occur at any moment of life, including in infants and children. The 
median age of diagnosis is 64 years. Age of 50 years is identified as cut-
off for the clinical subdivision of GBM patients. An older age is 
associated to a more negative prognosis. The patients with an age range 
between 70 and 74 years have a higher risk of death than those 65–69 
years old. This low chance of survival has been attributed to the decreased 
9 
 
ability to bear the neurological insults caused by the tumor and to tolerate 
surgery and / or other therapies.  
 
 Gender- GBM is more frequently diagnosed in men. Its incidence is 1.6 
times higher in males as compared to females with a higher frequency of 
primary GBMs men and secondary GBMs in women6. The survival rate, 
both in the man and in women, is greater in the first year after the 
diagnosis (36.7% and respectively of 32,8%). In the second year, it 
decreases notably with 13.7% in both the sexes. It gradually reduces 
subsequently, with a rate of survival after 5 years from the diagnosis of 
only, respectively, 4.7% and 4.6%. Therefore, men have a significant 
advantage of survival in comparison to women in the first year post-
diagnosis, but the difference it is not considerable hereinafter7.  
 
 Race/Ethnicity- Analyzing GBM incidence in US from 2006-2010, it has 
been shown that white people have higher incidence comparing to blacks, 
Asian/Pacific Islanders and American Indian/Alaska Native (about two 
times higher), and non-Hispanics have higher incidence as compared to 
Hispanic people. Nevertheless, studies on population do not prove a 
different race-based GBM survival rate. However, there is bound to be 
some correlations among race, therapy surgical received and survival of 
GBM patients7. 
These differences in incidence linked to race ethnic groups and gender, 
suggest the presence of identifiable, both biologic and environment based, 
causes. 
 
  Site- Although GBM tumours can rise anywhere in the brain, they are 
more commonly located in frontal, temporal, parietal and occipital lobes 
(supratentorial region of the brain). GBMs occur rarely in the cerebellum 
and in very rare cases they are present in the spinal cord. Cerebellar 
GBMs occur in younger patients compared to the tumours in the 
supratentorial area, (median age of 50–56 years in contrast to 62–64 years 
for patients with supratentorial GBM). Glioblastoma multiforme has a 
high tendency to spread aggressively and to generate tumours in other 
areas of the brain, named “satellite tumours”, which make them difficult 
to treat. Among supratentorial GBMs, frontal lobe tumors have better 
survival as compared to other sites8. 
 
 Other factors- Ionizing radiations are risk factor for GBM. Indeed, 
previous therapeutic radiation or working in the nuclear industry may 
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increase the risk of developing GBM. On the contrary, there is no 
evidence which suggests a correlation between GBM incidence and 
cigarette smoking, alcohol consumption and use of drugs. Many studies 
have found conflicting results about the linking of brain tumours with 
mobile phone use. The long-term risks of mobile phone use remain 
unknown9. 
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2.1.2. Prognostic Molecular Markers in GBM 
 
Glioblastoma is the most common and malignant form of glioma. Current 
treatments are only palliative and they only provide a survival benefit of 
some weeks or, at most, few years. Therefore, it is critically important to 
perfectly understand GBM biology and to give the best treatment to the 
patient, resolving in a better survival. 
TCGA, acronym for The Cancer Genome Atlas, is a project to create a 
catalogue of genetic mutations responsible for cancer. In 2008 it 
published a new classification of the GBM tumours, which organizes 
them into four different subclasses, Classical, Mesenchymal, Neural and 
Proneural, according to some molecular markers. This classification was 
widely used to predict survival time and treatment response kicking off 
new studies to better understand the molecular markers of GBM10. 
 
MGMT methylation 
Alkylating agents like Temozolomide (TZM) are specific drug used to 
treat GBM and some other cancers. They function by transferring alkyl 
groups to guanine bases causing DNA damage that can result in cellular 
death through apoptosis. MGMT is a DNA repair protein that is involved 
in cellular defence against DNA damage caused by alkylating agents. The 
protein removes alkyl groups from the O6 position of guanine in DNA, 
catalysing the transfer of the methyl groups resulting in the repair of the 
toxic lesions and preventing apoptosis. Thus, MGMT mediates resistance 
to TZM. Methylation of the gene promoter has been associated with 
several cancer types, including glioblastoma. Expression of MGMT is 
regulated by methylation of the promoter. Methylation causes the 
reduction of the expression of this protein and, therefore, it increases 
TZM sensitivity. In contrast, unmethylated MGMT promoter, increases 
protein expression given chemotherapy resistance. 
Thus, patients with a high level of methylation of the promoter survive 
longer than those with a low level11. 
 
Isocitrate dehydrogenase mutation 
IDH mutation is generally observed with low grade glioma. Conversely, it 
is only rarely associated with genetic alterations that we get used to see 
with high rates in primary GBMs (e.g., EGFR). This suggests that this is 
not a driver mutation in these GBM subtypes. On the contrary IDH 
mutation seems to be a driver mutation in low grade gliomas, likely 
through 2-HG production12. The most common mutation both in IDH1 
and in IDH2 is a single residue substitution of a histidine with an 
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arginine, representing a gain-of-function genetic change. The enzyme 
converts alpha-ketoglutarate (α-KG), the normal product, to D-2-
hydroxy-glutarate (D-2HG), a possible oncometabolite, altering cellular 
metabolism and response to hypoxic and oxidative stress. 
IDH mutated high grade gliomas arise from lower-grade gliomas and 
generally have a less aggressive clinical course compared to the primary 
GBM. Thus, these mutations are selective molecular markers of 
secondary GBMs differentiating them from primary GBM. Therefore, 
IDH mutated high grade gliomas have a more favourable prognosis than 
the ones without IDH1 mutation. 
Consequently, IDH mutations can influence the prognosis and may also 
predict tumour response to radiation and/or alkylating chemotherapy12. 
 
EGF Receptor 
EGFR or “epidermal growth factor receptor” is a tyrosine kinase receptor 
forming part of the ErbB family. This receptor is a cell surface protein 
able to bind epidermal growth factor. After binding, receptor dimerizes. 
This induces tyrosine auto-phosphorylation and determines the activation 
of a several signalling pathways and physiological responses which result 
in range of cellular activities, including growth, migration, survival and 
tumorigenesis. Studies demonstrated that in GBMs, EGFR signalling 
promotes cell division, tumour invasiveness, and resistance to 
radiotherapy and chemotherapy13. However, clinical studies have proved 
to be inconclusive to demonstrate the link between EGFR expression and 
poor prognosis. EGFRvIII (variantIII) is the most common mutation 
among EGFR amplified GBMs. About 50% of patients with EGFR 
amplification has this mutation due to deletion of exons 2–7, that results 
in a constitutively active form of the protein10.  
EGFRvIII over-expression has been shown to strongly predict poor 
prognosis in presence of EGFR amplification. Moreover, EGFR could be 
used as predictor for response to receptor tyrosine kinase (RTK) 
inhibitors, but it should be considered that EGFR-amplified tumours only 
initially respond to RTK inhibition becoming often resistant to the 
treatment.  
 
TP53 mutation 
The TP53 gene is a well-known tumour suppressor. It is involved and 
mutated in many cancers, playing a crucial role in tumour suppression. 
p53 is also a wide transcription factor, regulating more than 2500 genes, 
most of which affects tumorigenesis and tumour development14. Mutation 
of this gene has been reported in 60-70% of secondary GBMs and 25-
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30% of primary GBMs15. Apart from deletion of this gene, p53 pathway 
is generally modulated by a number of factors (MDM2, MDM4, and 
p14ARF as well as ATM and ATR, and so on), the alteration of which is, 
its own, involved in GBM development. According to TCGA data, 78% 
of GBM have mutations somewhere within this pathway14. Secondary 
GBMs have generally direct mutations of p53 gene. On the contrary, 
primary GBMs have more often an alteration in p53 regulators. Upstream 
of MDM2 is an important regulator of the p53 pathway. It negatively 
controls p53 by the use of two mechanisms: a transcriptional inhibition by 
direct binding, and the degradation through its E3 ligase activity. 
Primary GBMs often have a loss of INK4A/ARF (CDKN2A) gene locus. 
ARF (p14ARF) is a tumour suppressor protein which regulates p53 
directly binding to MDM2 and, thereby, inhibiting its E3 ubiquitin ligase 
activity. INK4a (p16INK4A), as well, plays a crucial role in growth 
control influencing pRB pathway.  
However, since p53 pathway influences several cellular responses, the 
prognostic and predictive role of this protein continues to be studied. 
 
 
Genetic losses of chromosomes 
 
Losses on chromosome 10 
One of the most common alterations in GBM patients is the loss of 
heterozygosity (LOH) for chromosome 1016. These losses can concern the 
entire chromosome or only one of its arms (short or long), so they could 
involve until 800 genes which are contained in it and encode proteins that 
plays different roles. Phosphatase and tensin (PTEN), is located at 
10q23.3 and it was the first tumour suppressor gene identified on this 
chromosome. Deletion of this gene occurs in 20-40% of GBMs, and they 
generally affect with higher frequency primary glioblastomas6. LOH for 
chromosome 10 seems to be an independent, adverse prognostic variable 
in high-grade glioma. Complete LOH for this chromosome are more 
commonly reported in grade 4 than grade 3 which, on the contrary, shows 
a higher frequency of partial loss compared to grade 417.  
Thus, considering high grade tumours, this kind of genetic alteration was 
correlated with an overall survival decrease. 
 
1p/19q status 
Co-deletion of the short arm of chromosome 1 and the long arm of 
chromosome 19 (1p/19q) is a genetic event found in 80% of 
oligodendrogliomas10. This happens when there is an unbalanced whole-
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arm translocation between chromosomes 1 and 19. It often occurs in IDH 
1/2 mutated GBMs, whereas it is mutually exclusive with TP53 mutation. 
According to TCGA, patients with grades II/III gliomas with an IDH 
mutation and 1p/19q-co-deletion lives longer than patients with an IDH 
mutation and no 1p/19q-co-deletion or compared to wildtype IDH18. 
This co-deletion predict response to chemotherapy and give better 
prognosis in anaplastic oligodendrogliomas, proving to be an independent 
prognostic marker associated with increased survival in both diffuse low-
grade and anaplastic tumours19. 
 
 
Figure 1. A schematic algorithm for classification of the diffuse gliomas. It provides 
a dynamic classification based on both phenotypic and genotypic features3. 
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2.2 GBM Symptoms 
 
According to where the tumour is localized, GBM symptoms can affect 
any of the brain’s functions since, growing up, it can press up against 
nerves or other CNS structures damaging them. This can interfere with a 
lot of brain functions such as memory, thought, emotion, movement, 
vision, hearing and touch. Thus, the most common symptoms of this 
disease are the following: 
 Frequent headaches, which make you up at the night or expand early in 
morning 
 Crisis or convulsions, which appear as sudden unintentional muscle 
contraction 
 Unexplained and intense nausea (feeling sick) with or without vomiting 
 Abnormal gait  
 Vision problems 
 Memory loss 
 Change in personality and irritability 
 Impaired concentration 
 Loss of vision, memory, impairment of speech and movement. 
Considering that there is no treatment for GBM, symptom management 
and palliative care remains the only option representing an essential 
aspect of the cure. 
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2.3. GBM Diagnosis 
 
Diagnosis generally initiates with a medical history, followed by some 
neurological examinations inter alia: 
 Reflexes 
 Coordination 
 Feeling 
 Pain response 
 Muscle strength 
 
These examinations are generally followed by imaging tests including: 
 Magnetic resonance imaging (MRI).  MRI is the primary and preferred 
test used to find a brain tumour and it uses potent magnetic fields, radio 
waves, and field gradients to generate detailed pictures of the brain and 
spinal cord. Before scanning, a special dye called contrast medium is 
injected or given to the patient as pill20. 
 
 Computed tomography (CT) scan. A CT scan is an imaging procedure 
that employs special x-ray measurements taken from different angles 
thanks to the rotation around the head. This technique produces cross-
sectional (tomographic) images (virtual "slices") of specific areas of 
scanned cranium, letting the doctor to see inside the object without 
cutting it. A CT scan can also be useful in tumour size measurement. Here 
too a contrast medium can be given before the scan to provide better 
detail on the image. 
 
 Positron emission tomography (PET) scans.  PET observes metabolic 
processes in the brain or other body parts, using gamma rays emitted 
indirectly by a positron-emitting radionuclide (tracer), which is 
introduced into the body on a biologically active molecule. Then a 
computer generates three-dimensional images of tracer concentration in 
the brain. Recently PET and CT scanners work together in the same 
machine during an only session. 
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Figure 2. Extensive glioblastoma multiforme in a 62-year-old man. Contrast-agent 
enhanced CT and MRI scan were fused with a FET-PET/CT examination and used to 
decide the right radiotherapy plan21. 
 
 
Unlikely, to look directly at the tumour tissue still remains the only way 
to be sure that a cancer is a glioblastoma, thus, biopsy from the tumour 
have to be taken and examined under the microscope. Consequently, 
these tests can only suggest that a GBM is present, but only a biopsy can 
give a definitive diagnosis. 
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2.4. GBM treatments 
 
Sadly until today, there is not cure for GBM. Thus, the treatment can only 
affect symptomatic aspects which aim to increase the survival rate and 
simultaneously to improve quality of life. 
Treatment depends on the patient's medical situations. Because of the 
extremely aggressive nature of glioblastoma, tumours are typically treated 
simultaneously by two or more methods (Table 4). Thus, in the 
beginning, treatment consists of an immediate maximal-safe surgical 
resection (if and when possible); this medical procedure is generally 
followed by RT and TMZ chemotherapy. Additional six rounds of chemo 
with TZM are used as maintenance treatment.   
Therefore, GBM cure includes surgery, radiation, and chemotherapy. 
 Surgery. Surgery is, in most cases, the first treatment step. It consists of 
the complete removal of the tumour, wherever possible, and sometimes a 
preventative surrounding healthy tissue resection. This helps to relieve 
symptoms, reducing tumour pressing on the nervous system structures 
and allows the definitive diagnosis. In certain cases, the tumour cannot be 
completely removed, because cancer cells grow into surrounding brain 
tissue, making surgery difficult. This is the reason why the treatment 
includes additive therapy to kill the remaining cells. In some instances, 
surgery can damage part of the brain resulting serious consequences in the 
movement, breath, swallowing or consciousness. Furthermore, some 
GBM, named inoperable or unresectable, cannot be surgically removed 
because of their location and in these cases other treatments have to be 
given. 
 Radiation. Radiations are the use of high-energy x-ray beams to destroy 
tumour cells stopping or slowing tumour growth. They kill cancer cells by 
damaging their DNA directly or creating charged particles (free radicals).  
The most common type of radiation treatment is named external-beam 
radiation therapy which aims high-powered x-rays at the tumor and 
surrounding tissues from outside the body. Interstitial radiation or 
brachytherapy is another radiotherapy that employs implants; in this case 
radioactive material is placed directly into the tumor. Proton therapy, 
called also proton beam therapy, is a further type of radiation treatment 
used for brain tumours; it uses protons to treat cancer. Here, radiations are 
delivered with no pain through the skin from a machine outside the body. 
This approach provides pinpoint focusing of the radiation beam to the 
tumor, by reducing damage to surrounding normal brain tissue. 
Unfortunately, radiation therapy can also damage normal cells, leading to 
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several side effects. Some of the main side effects are the following: 
tiredness and weakness, sore skin, loss of hair, dry mouth, infertility, 
nausea and vomiting.  
 Chemotherapy. Chemotherapy is the use of drugs to destroy or to stop 
the growth of cancer cells. The doctor can give a single drug or a 
combination of different drugs simultaneously which can be taken by 
mouth (oral administration), injected into a vein (intravenous 
administration) or in a muscle (intramuscular injection). 
Chemotherapeutic drugs can also be given directly into the spinal canal, 
in a procedure named intrathecal chemotherapy; this allows treating cells 
on the surface of the brain and spine. This procedure is still an 
experimental treatment and cannot be available everywhere. TZM is the 
most used chemotherapeutic drug for GBM, and it is an alkylating agent. 
Another alkylating agent is Carmustine, it also applied as infused 
biodegradable discs, implanted after glioma surgery resection 
(Gliadel®)22. As well as radiotherapy, chemo can lead to several side 
effects. Some of the main side effects are: fatigue, risk of infection, 
nausea and vomiting, hair loss, loss of appetite, and diarrhoea. 
 
 
Table 4. Summary of current therapy for Malignant Gliomas in adults. The table 
indicates standard therapy for newly diagnosed malignant gliomas, it involves surgical 
resection when possible, radiotherapy, and chemotherapy23. 
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2.5. Remission and recurrence 
 
Remission is the situation in which the cancer is undiagnosable or there 
are no symptoms. This situation can also be named having “no evidence 
of disease” or NED.  
 Two different type of remission exist: 
 Partial remission. A partial remission is when the tumour is still there, 
but it is smaller as a treatment result, so the patient can reduce or suspend 
the treatment as long as the cancer doesn’t begin to grow again.  
 Complete remission. Complete remission, named also NED, means that 
the cancer cannot be detected by tests, physical exams, and scans. The 
term Complete remission or NED is preferred to the word “cure” because 
the remission may be also just temporary thus, unlikely, cancer cells can 
come back. 
If the tumour comes back, it commonly happens within 5 years following 
the first treatment. Thus, the patient should continue to check for signs of 
cancer periodically after a complete remission. 
 Recurrent tumour is a tumour which returns after the original treatment. 
Understanding the risk of a recurrence is very important to feel yourself 
more prepared if the tumour does return. Cancer that comes back in the 
same place is named local recurrent tumour, similarly if it comes back 
nearby or in another place it is called regional or distant recurrent tumour 
respectively. The treatment plan often includes the same therapy 
described above, but they can be used in a different combination. 
If treatment fails, so if the cancer cannot be cured or controlled, the 
tumour is called advanced or terminal cancer. 
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3. Stem Cells  
 
Stem cells are progenitor of more than 200 cell types forming adult body. 
They are unspecialized cells contributing to tissue generation, 
maintenance and repair.  
Stem cells possesses two main features: Self renewal and Unlimited 
potency. Self renewal is process by which stem cells divide by 
maintaining their undifferentiated state, thus giving rise to more stem 
cells with basically the same non-specialized phenotype and replication 
potential. It occurs through a symmetric division to generate two identical 
cells. Instead, potency refers to their ability to produce daughter cells able 
to differentiate into different types of specialized cells. It occurs through 
an asymmetric cell division to generate one cell that is identical to the 
mother cell and one different cell, named progenitor cell, that will 
generate through differentiative steps the specialized cell.  
Stem cells can have several grades of potential. Totipotent cells are cells 
capable of differentiating into all the specialized body cells, including 
extraembryonic tissues24. Pluripotent stem cells can produce any of the 
three different types of human embryonic leaflet, giving endoderm, 
mesoderm or ectoderm cells. Thus, these cells can produce any type of 
body cells except extra-embryonic tissue. Multipotent cells are able to 
differentiate into a limited number of other cell types.  
Normal adult stem cells can be find in many tissues. As demonstrated by 
scientists, adult stem cells are also present in brain and heart, two 
locations where they were not previously supposed to reside. Now stem 
cells are increasgly becoming therapeutic tools for regenerating tissues25.  
Systemic or local signals regulate cell division of stem cells influencing 
senescent or damaged cells replacing and ensuring organs correct 
functions26. Thus, self renewal and differentiation processes are tightly 
controlled in order to maintain and repair adult tissues by responding to 
environmental changes. Researchers showed that failure of this 
sophisticated control mechanism underpins tumour occurrence and 
development27. 
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4. Cancer Stem Cell Theory 
 
Survey after survey shows that tumours contain a small population of 
cells, named cancer stem cells (CSCs)28,29, which is responsible for tumor 
initiation, growth, and recurrence and is liable for cancer chemotherapy 
resistance30. Thus, cancer is now recognized as a heterogeneous group of 
cells showing several differentiation phenotypes. 
CSCs are a very little population representing about 0.05-1% of the 
cancer cells, despite this they result to be crucial for chemoresistance and 
recurrence31,32. These cells share with the normal stem cell several 
characteristics, the most important of which are self-renewal and 
differentiation. Unlikely, they gain also numerous additional abilities 
including: 
 Self-sufficiency in growth signals, it is the ability to proliferate 
aberrantly. 
 Insensitivity to anti-growth signals, they resist to anti-proliferative 
growth signals. 
 Evading apoptosis, ability to resist to programmed cell death. 
 Limitless replicative potential, they are able to proliferate indefinitely. 
 Sustained angiogenesis, they can stimulate the growth of blood vessels 
to supply nutrients that they need. 
 Tissue invasion and metastasis, it refers to the ability to invade local 
tissue and spread to distant sites. 
CSCs origin is still unclear, they could derive from normal adult stem 
cells after accumulating of oncogenic mutations or from differentiated 
cancer cells which undergo a reprogramming-like process acquiring stem-
like properties. It has been showed that many embryonic stem cell 
signalings are reactivated in stem cells involved in several cancers33. For 
instance, Nanog, an embryonic stem cell-specific transcriptional factor, is 
highly expressed in several CSCs implicated in hepatic, colorectal, and 
brain tumours34-36.  
CSC subpopulations can be sorted on the basis of their cell surface 
marker profiles37 or identified by tumorsphere culture, using their ability 
to grow in the absence of serum and without attachment to culture plates, 
so in condition in which differentiated cells cannot survive38. It appears 
clear that CSCs contribute to treatment failure39, moreover only a small 
number of these cells is enough to initiate a tumour.  
In summary, one of the greatest limitations of the currently therapeutic 
approaches is that they are failing to eliminate CSCs, as CSCs result to 
cause a multiple drug resistance (MDR) of the tumour40.  Since CSCs 
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survive conventional therapies, they often lead to tumour recurrence 
(Figure 3). Therefore, many studies have focus on selection of new tools 
and novel therapies aiming to eliminate CSCs and strongly reduce cancer 
recurrence. 
 
 
Figure 3. Schematic representation of Cancer Stem Cells Theory. Here it is 
illustrated the effect of current clinical treatments on tumour cell populations. Unlikely, 
current radiotherapy and chemotherapies target only highly proliferative cells, but they 
appear to be unable to target that small population of quiescent cells (GSCs) which, over 
time, are responsible for tumor recurrence. 
 
 
GBM as well is a heterogeneous tumour, consisting of normal cells and a 
small population of CSCs; thus, identifying a selective therapy against 
GSCs is of the utmost importance in the fight against GBM. 
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5. Aptamers  
 
The term “Aptamer” was coined by Andy Ellington in 1990. It stems 
from the greek terms “aptus,” meaning to fit, and “meros,” meaning part. 
Aptamers are single-stranded oligonucleotides, DNA or RNA molecules, 
able to bind tightly to a target molecule cause the “fit" to their target 
acting directly by binding the protein target with high affinity41. Thereby, 
thanks to their three-dimensional conformation, aptamers are known to 
recognize their specific target with high affinity and selectivity.  
Aptamers are selected by using a technique named SELEX. Up to now, 
from the SELEX we achieved more than 900 aptamers42. The most 
common targets are proteins, although aptamers can bind a wide range of 
targets such as inorganic ions, small organic ligands, amino-acids, 
nucleotides and derivatives, oligonucleotides, antibiotics, peptides, 
proteins, sugars, parasites, virus, cells and tissues.  
Especially in oncology there has been a noticeable increase in aptamer 
field. In a medicine which needs to be more and more specific to 
selectively destroy cancer cells sparing healthy cells, along with the 
necessity of personalizing the treatment according to the different type of 
tumours, highly specific tools, such as aptamers, are becoming more and 
more attractive instruments in fighting cancer. In addition, their specific 
binding to cell surface receptors will allow not only molecular imaging 
but also the direct delivery of drugs into cancer cells expressing the target.  
 
 
Figure 4. Engineering aptamers binding specific targets.  Aptamers are single-
stranded DNA or RNA sequences able to tightly bind to target molecules thanks to their 
3-dimensional structures. Picture source: 
http://www.idtdna.com/pages/decoded/decoded-articles/core-
concepts/decoded/2016/03/15/planning-to-work-with-aptamers 
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Moreover, aptamers possess several advantages over antibodies: there are 
synthetically created reducing the production costs; they are more stable 
both at room temperature and at elevated temperature (after which they 
are able to self-refolding) compared to antibodies; moreover, they are 
smaller than antibodies and thus, they have a higher tissue penetration; 
furthermore, aptamers have no toxicity or immunogenicity and they can 
easily be chemically modified. Another very important aspect of aptamers 
is also their ability, in some cases, to cross the blood brain barrier (BBB) 
making them attractive instruments for brain cancer43,44. 
Aptamers can be distinguished in ssDNA and RNA aptamers. The first 
ones are more stable and cheaper than second ones, but their preparation 
during the SELEX is more challenging than RNA aptamers which give 
also more diverse three-dimensional structures than ssDNA aptamers. 
 
 
5.1. Aptamer modification 
 
Being aptamers nucleic acids, they have two major drawbacks. One of 
them is their nuclease sensitivity, especially regarding RNA aptamers; 
this would lead rapid elimination from the blood45 resulting in 
pharmaceutical development difficulties. The second one is that aptamers, 
with their only 4 nucleotides, can have a lower chemical diversity 
compared to 20 amino acids based library. Fortunately, aptamers prove to 
be very easily chemically modifiable; these modifications allow 
overcoming these two aptamers limits. Generally, the nucleophilic 
cleavage occurs on the 2’-OH group; thus, modifying this group, nuclease 
sensitivity is greatly reduced. 2’-OH group of pyrimidines can be easily 
replaced with 2’-fluoro (2’-F) or 2’-amino (2’-NH2) group. Other 
modified nucleotides can be 2’-O-methyl nucleotides, 2’-thio (2’-SH), 2’-
azido (20-N3), locked nucleic acid (LNA) or hexitol nucleic acid (HNA). 
Modifications can be incorporated via an efficient engineered mutant T7 
RNA polymerase, embedded in the SELEX library or, in case of they do 
not rearrange aptamers shapes, can be introduced post-selection. 
In order to expand the chemically diversity of aptamers Gold et al46. 
created a new class of aptamer, the Slow Off-rate Modified Aptamer 
(SOMAmer), by the incorporation of four modified 
nucleotidentriphosphate analogs: 5-benzylaminocarbonyl-dU(BndU), 5-
naphthylmethylaminocarbonyl-dUn(NapdU), 5- tryptaminocarbonyl-dU 
(TrpdU), and 5-isobutylaminocarbonyl-dU (iBudU); these modifications 
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enhance binding affinity and enables a slower complex dissociation rate. 
Thus, SOMAmers are currently employed to discover and validate 
biomarkers by using SOMAscan™ assay.  
Another way, used by the company NOXXON Pharma AG (Berlin, 
Germany), to prevent aptamers enzymatic degradation consists of using 
spiegelmers (‘spiegel’ means ‘mirror’ in german). Spiegelmers are 
synthetic RNAs made of L-ribose instead of D-ribose units, this chemical 
modification give an increased resistance to nuclease degradation and 
more stability in vivo. In this case, the SELEX is performed with D-RNA 
library on the mirror image of the protein (artificially synthesized) with 
D-aminoacids. Once the aptamer is selected, it is converted to L-RNA, 
understandably this approach can be applied only by using synthetically 
targets. 
Additional modifications may concern the improvement of aptamers half-
lives. Therefore, ssDNA and RNA aptamers are often conjugated to bulky 
groups, such as poly (D, L-lactic-co-glycolic acid) (PLGA), poly ethylene 
glycol (PEG), liposomes, streptavidin or cholesterol, which can strongly 
reduce systematic clearance47. 
 
 
5.2. SELEX technology 
 
SELEX is the technique through which aptamers are selected; SELEX is 
an acronym which stands for ‘selective evolution of ligands by 
exponential enrichment’. It represents a chemistry technique used in 
molecular biology to select single strand nucleic acids able to specifically 
bind target molecules. The selection starts from a very large 
oligonucleotides library consisting of 1014-1015 ssDNAs or RNAs which 
have a central randomly degenerated sequence flanked by constant 5’ and 
3’ regions, containing binding sites for primers (and T7-RNA polymerase 
binding site for RNA-SELEX). For a degenerated region of length n, 4n 
are the possible obtainable sequences. The sequences are placed in 
contact with target; during the partitioning step, nucleic acids able to bind 
the target are recovered instead sequences which do not bind are washed 
away. Then, thanks to the fixed regions, binding molecules are amplified 
by PCR or RT-PCR according to whether ssDNA or RNAs are 
respectively used as oligonucleotides. A round of SELEX consists of 
three steps: 
1. Selection, sequences are exposed to the target 
2. Partitioning, binding sequences are selected but the unbound sequences 
are washed away. 
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3. Amplification, binding sequences are amplified and used for the next 
SELEX round. 
The number of rounds can be decided according to personal needs.  
Rounds can be made more complex by adding negative selection to 
environmental elements (such as supports like filters or beads) and/or by 
the addition of a counter selection step against not target molecules (like 
negative cells or related proteins). These additional steps can be inserted 
either before or after the positive selection to remove non-specific binding 
aptamers.  
The choice of what to use as positive-, negative- or counter-selection is of 
highly important for the selection. 
As shown in figure, two are the main methods used to identify aptamers, 
one is the classical protein-SELEX approach and another one is the more 
accurate cell-based SELEX procedure.  
 
 
 
 
Figure 5 Scheme of protein- and cell-based SELEX processes.  Continue. 
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Figure 5 Scheme of protein- and cell-based SELEX processes.47 Briefly, the process 
of SELEX involves three steps: selection, partitioning and amplification. The selection 
shall be carried out by using the target cells. During the partitioning nucleic acids able to 
bind are recovered. Finally, they are amplified and used for the next SELEX cycle. In the 
end of SELEX, the obtained nucleic acid molecules are cloned and sequenced. 
Individual sequences are aptamers. (a) Protein-based SELEX. The pre-identified purified 
protein is used as target for this kind of SELEX. It is visible in red. (b) Cell-based 
SELEX on a pre-identified tumor cell-surface biomarker colored in red. (c) Cell-based 
SELEX on a post-identified tumor cell-surface biomarker. The target is shown in red, it 
is identified at the end of the SELEX process. (d) Cell-based SELEX to a tumor cell 
type. In this case, no particular cell-surface biomarkers are identified and aptamers are 
specific to the cell’s molecular signature. The whole cell used for positive selection is 
colored in red. 
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5.3.  Protein-SELEX technique 
 
Protein-SELEX represents the easiest form of SELEX. Full-length or 
truncated versions of full length proteins can be used during this 
technique. Proteins are generally coupled to tags (His-tags, Fc fragments 
of antibody or GST), in order to make it easier to purify and select by 
affinity. This technique presents various limits; some of them are the 
difficult to extract, purify and solubilize membrane protein from the lipid 
membrane or often large amount of proteins are required for a whole 
protein-SELEX. Furthermore, some membrane proteins expressed in 
prokaryotic or lower eukaryotic systems may not have or have different 
post-translational modifications, compared to eukaryotic cells; these 
differences (phosphorylation, glycosylation, ubiquitination, methylation, 
myristylation, acetylation) can significantly alter protein structure 
reducing or completely eliminating aptamer binding48. 
Broadly, the major downside of protein-SELEX is that these purified and 
solubilized proteins have a very different structure which is a long way 
from the physiological conformation. Therefore, some aptamers selected 
with protein-SELEX failed to recognize their cell-surface targets in its 
endogenous environment. Moreover, some biomarkers need co-receptors 
for their appropriate folding. This limitation can be overcome by using a 
cell-based SELEX. 
 
5.4. Cell-Based SELEX 
 
As shown in Figure. b-d, the whole cell represents the target of cell-based 
SELEX. Here, differently than protein-SELEX, target is in its native 
environment on the cell surface and, because of that, it is in its 
physiological conformation by enabling the right selection of aptamers 
able to bind it also in vivo.  
Many papers have been published on cell-SELEX approach, especially 
linked to cancer.  
In internalized cell-SELEX, aptamers are selected on the basis of their 
ability to be internalized after target binding. According to the target of 
the cell-SELEX, we can have: 
 Pre-Identified Tumor Cell-Surface Biomarkers, when the objective of 
the SELEX is to select aptamers for an identified and known biomarker 
expressed on cell surface (Figure. b). This technique may be combined to 
a protein-SELEX generating a hybrid-SELEX; thus, the first rounds of the 
selection are performed on cells and last SELEX cycles are made on 
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purified protein. A reverse hybrid-SELEX couples first protein-SELEX 
and later cell-SELEX. 
 Post-Identified Tumor Cell-Surface Biomarkers, when the target is 
identified after the cell-SELEX. This kind of SELEX is very important 
because it allows identification of new biomarkers (Figure c). Thus, there 
is first aptamers selection against a tumor cell type followed by target 
identification which could represent a new biomarker. The identification 
results often to be challenging, it is generally shall be affected by affinity 
purification followed by mass-spectrometry. The first post cell-SELEX 
identification was realized by Daniels et al49.in 2003. They identified 
Tenascin-C as target of GBI-10 aptamer, selected using U251 
glioblastoma cell line as positive selection. It is not a cell-surface 
receptor, but an extracellular matrix protein. 
 Undetermined Targets, when aptamers are selecting against a tumour 
cell type without pre- or post-identification of targets. In this instance, 
aptamers result to be specific for a molecular signature (Figure d). 
Targets, during a cell-based SELEX, are certainly closer to their natural 
distributions and conformations; this gives more assurance about a good 
selection of the aptamers, moreover contrary to a protein-SELEX, cell-
based SELEX, offers the opportunity to identify a new tumor protein 
biomarker. However, this type of selection is more complex than protein-
based SELEX; a high number of cells are needed, therefore sell lines have 
to be available, cultivable and stable. In addition, it is generally difficult 
to select aptamers specific for a less expressed target on cells and 
sometimes cells have to be modifying over- and/or under-expressing cell-
surface protein target for selection and/or counter-selection and this may 
lead modifications of the cell line which can do not represent the disease 
cellular context anymore. Furthermore, it has been proved that cell-
SELEX needs more selection/counter-selection rounds than protein-
SELEX to achieve selective aptamers for the targets. Finally, aptamer-
mediated target identification is often not an easy procedure. 
 
 
5.5. Applications of Aptamers in Oncology 
 
5.5.1. Aptamers as Detection and Imaging Reagent 
 
A timely detection of biomarkers indicating disease is of great 
importance, especially in the cancer context, where the timeliness is 
essential. Aptamers, being a class of bio-recognition molecules, may be 
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used as diagnostic tool. Biomarker detections is made possible by using 
aptasensors (aptamers used as biosensors), by converting the aptamer 
conformational change, caused by the binding to the target, into 
measurable signals. Sun et al. in 2016 showed the detection of soluble 
tumour biomarkers through the use of aptamer-based analytical platforms 
with low limits of detection50. Aptamers can also be utilized, in the 
contest of circulating tumours, in sensitive diagnostic assays51,52.  Bukari 
et al53. in 2017, developed a method by which aptamers are used in 
histopathological diagnosis.  
A very important aptamers issue concerns their application as imaging 
agents; in this case, they are combined with radionuclide or fluorescent 
labels, bioconjugates or nanoparticles, representing therefore a non-
invasive manner for defining the tumor tissue border. This is a very 
tempting opportunity in cancer, especially in brain cancer in which 
perfectly defining tumour border could allow to completely eliminate the 
tumour and, simultaneously, do not eliminate healthy tissue.   
 
 
5.5.2. Aptamers in Therapy 
 
Aptamers, after interaction with their targets, can act as agonist or 
antagonist by activating or blocking target cellular functions respectively. 
Several aptamers, such as CD28, OX40 and 4-1BB, have been proved to 
have immunomodulatory activity if they are used both alone and in 
combination with first-line treatments in cancer therapy54. 
Given the ability of some aptamers to be internalized following the 
binding to the target, they can be used as a delivery tool of therapeutic 
agents. Thus, aptamers able to be internalized are cargoes which carry 
therapeutic agents inside the cytosol of specific targeted cells55; this 
constitutes a very pioneering aspect considering that current anticancer 
treatments are definitely not selective, affecting both cancerous and 
healthy cells and consequently generating very strong adverse effects. 
 Therapeutic agents can be coupled to aptamers both in a non-covalent 
and covalent manner, by forming aptamer chimeras which are composed 
of an aptamer and therapeutic molecules (such as small interfering RNA, 
micro RNA, anti-microRNA and small hairpin RNA or anti-tumor drugs 
or toxins etc.)56. Therefore, aptamer chimera appears to have a very 
promising role in a more selective medicine. 
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5.6. Aptamers approved or in Clinical Trials 
 
Currently eleven are the aptamers approved or under examination during 
clinical trials. Three of them are involved in eye disorders, four in 
coagulation, two concern inflammation and two are implicated in cancer 
treatment response57. Generally, aptamers target are proteins which are on 
cell surface; this means that aptamer activity can be reversed by using of 
an oligonucleotide antidote, as in the case of pegnivacogin. Pegnivacogin 
is an antithrombotic aptamer, whose action can be reversed by 
anivamersen, a 15-nucleotide long 2’-O-methyl RNA. 
Almost all the aptamers, listed in Figure 6, have a PEG-modification. As 
mentioned before in 4.2, this modification can strongly limit renal 
clearance and enhance aptamer stability, increasing its molecular weight 
and prolonging its circulating half-life. Unlikely, Pegnivacogin clinical 
trials was stopped because of 3 patients on 640 who presented allergic 
reaction (two anaphylactic and one dermal); however, it was observed 
that pegnivacogin or its degradation was not responsible for these allergic 
reaction, as well as inflammation response or histamine release, but these 
reactions were caused, in the three patients, by their high levels of 
antibody to PEG. 
 
5.6.1. Aptamer therapeutics for age-related macular degeneration 
(AMD)   
 
Pegaptanib sodium or Macugen®  
Macugen® (Eyetech Inc and Pfizer) is a 27 ribonucleotide aptamer, it was 
the first aptamer drug approved by Food and Drug Administration, in 
December 2004. This disease appears as a vision loss in older adults due 
to retinal damage. It has been demonstrated that Macugen® is able to 
block macular degeneration by inhibiting vascular endothelial growth 
factor (VEGF), a signal protein that stimulates vasculogenesis and 
angiogenesis58. Thus, a 0.3 mg/eye Macugen® dose, administered once 
every 6 weeks by intravitreal injections, is sufficient as anti-angiogenic 
medicine to treat wet age-related macular degeneration. Moreover, 
Macugen® has also potential therapeutic effects to deal with solid cancers 
characterized by extensive angiogenesis. 
E10030 (Fovista™) 
Studies have proved that the AMD treatment is more effective if anti-
VEGF agent is combined to an aptamer able to bind to platelet-derived 
growth factor (PDGF). Fovista™ is a 29 nucleotide-long DNA aptamer, 
developed by Ophthotech Corp, capable to bind PDGF; it is standing by 
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to enter in phase III. Studies are testing 0.03, 0.3, 1.5, 3 mg of E10030 in 
combination with an anti-VEGF agent, once a month for 3 months; for the 
time being, this appears to enhance visual outcome57. 
ARC1905 
ARC1905 (Ophthotech Corp) is a 39 ribonucleotide aptamer whose target 
is complement component 5 (C5), which is a pro-inflammatory protein 
forming part of the innate immune system; it is found in crystalline 
deposits under the retina in AMD. Inhibition of C5 prevents the 
progression of the macula, being therapeutic in both in wet and in dry 
AMD. 
 
 
5.6.2. Therapeutic aptamers for hemostasis 
 
RB006  
RB006 is a 34 nucleotide RNA aptamer which binds to factor IXa; along 
with complementary active control oligonucleotide, RB007; it forms the 
anti-coagulant system named REG1. This system inhibits an important 
step in prothrombin assembly and thrombin generation by blocking the 
factor VIIa/IXa catalyzed conversion of factor X to factor Xa57. A single 
subcutaneous dose of 1 mg kg-1 has proved to achieve high plasma 
concentrations and maintain near complete inhibition of factor IX activity 
for several days after administration. Currently, REG1 system is waiting 
to enter in phase III. 
ARC1779 
ARC1779 (Archemix Corp) is the second aptamer involved in 
coagulation disease. It is formed by 39 ribonucleotides, and it is able to 
bind the A1 domain of activated von Willebrand factor (vWF). This 
binding is responsible for decreasing platelet adhesion and aggregation, 
and thereby for reducing thrombus growth in arterial beds. Thus, by 
inhibiting vWF factor, it can be used to treat acute coronary syndromes, 
von Willebrand disease, vWF-related platelet disorders such as 
thrombotic thrombocytopenic purpura (TTP) and other thrombotic 
microangiopathies59. Currently, phase II trial is ongoing. 
NU172 
NU172 is a DNA aptamer composed by 26 unmodified nucleotides; it 
was developed by Nuvelo and ARCA Biopharma. It inhibits blood protein 
thrombin, preventing its cleavage by the fibrinogen. Phase II is ongoing 
also for this NU172, which is proving to can be used as a rapid 
anticoagulant for invasive medical procedures60. 
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BAX499  
BAX499 or ARC19499 is an RNA aptamer which is, right now, subjected 
to a Phase I clinical trial. It is the last of the four aptamers involved in 
coagulation disorders. It treats hemophilia. Hemophilia is a rare genetic 
blood clotting disorder; it subdivides into hemophilia A and B, according 
to factor VII or factor IX is implicated. This disease results in deficient 
blood coagulation via the intrinsic pathway. BAX499, allow clot initiation 
via the extrinsic coagulation pathway, by binding to tissue factor pathway 
inhibitor (TFPI), which negatively affects this pathway61.  
 
5.6.3. Therapeutic aptamers for cancer 
 
AS1411 
AS1411 or AGRO100 is an DNA quadruplex aptamer which binds the 
extracellular domain of what everyone knew better as a nuclear protein. 
Its target is nucleolin, a multifunctional protein located in the nucleolus 
but overexpressed at the membrane of several cancer cells. This protein is 
implicated in cell survival, growth and proliferation, nuclear transport, 
and transcription. It, in fact, is able to interact with key oncogenes (bcl-2, 
Rb, p53, Akt-1) and to transfer specific extracellular ligands into the cells. 
Nucleolin inhibition by AS1411 binding acts on several signaling 
pathways, including NF-ĸ-B62 and Bcl-263. AS1411 was the first aptamer 
approved by FDA for phase I clinical to test different type of cancer and 
the first-in-class drug known to specifically target nucleolin. Clinical 
trials show promising signs of activity, thus AS1411 is currently under 
phase II trial to treat acute myeloid leukemia64,65 and metastatic renal cell 
carcinoma66. 
NOX-A12 
NOX-A12 (Spiegelmer®, NOXXON Pharma AG, Berlin, Germany) is a 
45 nucleotide-long spiegelmer which targets and blocks stroma cell-
derived factor 1 (SDF-1 or CXCL12)67. This protein is a chemokine 
intermediate which, via interaction with the receptors CXCR4 and 
CXCR7, is involved in stem cell migration to the bone marrow and 
induces vasculogenesis, tumor growth, and metastasis. As mentioned 
above, having L-ribose units, NOX-A12 is highly resistant to degradation 
by abundant nucleases. NOX-A12 is currently under phase II trial to treat 
chronic lymphatic leukemia and multiple myeloma, both alone and in 
combination with chemotherapeutic agents68. 
 
 
35 
 
5.6.4. Therapeutic aptamers involved in inflammation 
 
NOX-E36 
NOX-E36 (Emapticap pegol) is also a Spiegelmer aptamer created by the 
company Noxxon; its length is 40 nucleotide-L-RNA. NOX-E36 targets 
and inhibits the pro-inflammatory chemokine C-C motif-ligand 2 (CCL2), 
also named MCP-1 or Monocyte Chemoattractant Protein 1. NOX-E36 is 
in clinical development for the treatment of type II diabetes mellitus, 
nephropathy, and lupus nephritis. Studies, carried out to date, have proved 
that NOX-E36 is generally safe and well tolerated, reduces the urinary 
albumin/creatinine ratio and has beneficial effects on glycated 
haemoglobin in type 2 diabetic patients with albuminuria69. 
NOX-H94 
NOX-H94 (lexaptepid pegol) is a specific spiegelmer for hepcidin. 
Hepicidin is a peptide hormone which plays a key role in the iron 
metabolism reducing iron concentrations in the blood. Thus, NOX-H94 is 
under phase II trial to treat anemia of chronic disease70. This anemia, 
known also as anemia of chronic inflammation, is a form of anemia seen 
in chronic infection, chronic immune activation, and malignancy; it is 
generally characterized by impaired erythropoiesis due to functional iron 
deficiency, often caused by excessive hepcidin. Hepcidin in fact degrades 
ferroportin which is the iron cellular channel reduce available iron in the 
blood for hemoglobin production required for red blood cells formation. 
Therefore, NOX-H94, offering a hepcidin-specific approach, causes iron 
release from the storage cells providing a new therapeutic tool to treat 
patients with anemia who do not respond properly to current therapies. 
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Figure 6.  Therapeutic aptamers. Here aptamers in on-going or completed clinical 
trials for therapeutics are shown71. 
  
Therapeutic 
Purpose
Name Target Form Modification Status
Macular 
degeneration
Pegaptanib
Vascular 
endothelial 
growth factor 
(VEGF)
RNA
Ϯ′-fluoro 
pyrimidines, Ϯ′-O-
methyl purines, ϯ′-
inverted dT, 
PEGylated
Approved for age-
related macular 
degeneration (wet 
AMD)
ARC1905
Complement 
component 5
RNA
ϯ′-inverted dT, 
PEGylated
Phase I completed
E10030
Platelet-derived 
growth factor 
(PDGF)
DNA
Ϯ′-fluoro 
pyriŵidiŶes, Ϯ′-O-
ŵethyl puriŶes ϯ′-
inverted dT
Phase III await
Cancer
AS1411 Nucleolin DNA G-rich, PEGylated Phase II on-going
NOX-A12
The chemokine
(C–X–C motif) 
ligand 12 (CXCL-
12)
L-RNA L-form, PEGylated Phase II on-going
Coagulation
RB006 
Coagulation factor 
IXa
RNA
ϯ′-inverted dT, 
PEGylated
Phase III await
ARC1779
von Willebrand 
factor (vWF) A1 
domain
DNA
ϯ′-inverted dT, 
PEGylated
Phase II on-going
NU172 Thrombin DNA Unmodified DNA Phase II on-going
BAX499
Tissue factor 
pathway
RNA
ϯ′-inverted dT, 
PEGylated
Phase I on-going
Inflammation
NOX-H94 Hepcidlin L-RNA L-form, PEGylated Phase II on-going
NOX-E36
The chemokine 
(C–C motif) ligand 
2 (CCL2)
L-RNA L-form, PEGylated Phase II on-going
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6. Aim of the study 
 
Glioblastoma is the most common primary brain tumour of adulthood and 
the most malignant glioma. The median overall survival of patients is 
very low, standing at around 15 months. Unlikely, despite many studies 
aimed to improve treatment efficacy, the overall survival has not 
increased in a significant way in the last years. This poor prognosis is 
strongly caused by the almost universal recurrence of glioblastoma 
tumour. Thus, recurrences seem to be inevitable event for GBM patients 
showing up within 6-9 months after treatment. The prognosis of a 
recurrent patient is poorer than the first one, with a median survival of 
only 3-6 months.  Glioblastoma Stem Cells appear to be closely involved 
in tumour development, metastasis and recurrence. Therefore, it is clear 
how important it is to target GSCs in order to increase GBM patient 
overall survival. Accordingly, the present work aims to identify selective 
aptamer ligands for glioblastoma stem cells as new therapeutic tools for 
glioblastoma. It can be strongly assumed that a specific therapy against 
GSCs can considerably reduce GBM malignancy with an impressive 
prolonged patient survival. 
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7. Materials and methods 
 
Glioblastoma stem-cell isolation and differentiation 
GBM tissue samples were obtained from the Institute of Neurosurgery, 
School of Medicine, Università Cattolica, Rome, Italy after craniotomy of 
adult patients (as described by Pallini et al.) from which, before surgery, 
informed consent was obtained. Stem cells were isolated through 
mechanical dissociation of GBM tumor specimens and cultured in a 
serum-free medium supplemented with EGF and bFGF as previously 
described. To induce differentiation, cells were plated on flasks coated 
with BD Matrigel™ Basement Membrane Matrix (BD Biosciences) in 
presence of 10% serum and absence of EGF and bFGF for 2 weeks. 
 
Whole-Cell SELEX 
The SELEX cycle was performed essentially as described by Fitzwater T 
et al. 1996. Given the resistance to degradation against seric nucleases 
provided by the fluoropyrimidine, transcription was performed in the 
presence of 1 mM 2′-F pyrimidines and a mutant form of T7 RNA 
polymerase (2.5 u/µl T7 R&DNA polymerase, Epicentre Biotechnologies, 
Madison, WI.) was used to improve yields. The complexity of the starting 
pool was roughly 1014. Before each incubation with the cells, the 2'F-Py 
RNAs were heated at 85°C for 5 min, snap-cooled on ice for 2 min, and 
allowed to warm up to 37°C. 
Selection step. In order to sort aptamers able to selectively bind GSCs, a 
selection step was performed incubating the pool with 107 GSCs cells at 
37°C for 30 min up to 14th round or for 15 min in the last two rounds of 
SELEX. The bound aptamers were recovered after washings (one for the 
first two cycles and two for the others cycles) with 5 ml of DMEM-F12 
serum free. 
Counterselection step.  To select sequences recognizing specifically the 
GSCs cells, before the selection step, a counterselection against 
glioblastoma differentiated cells was performed in order to not select 
aptamers which identify also the glioblastoma differentiated cell surface. 
In this case the pool was first incubated for 30 min (one time up to 13th 
round and two times in the last three rounds) with 107 GSCs (150-mm cell 
plate), and unbound sequences were recovered for the selection phase. 
During the selection process, we increased number of counterselections or 
of washings and decreased incubation time to progressively raise the 
SELEX selective pressure. The use of poly inosinic acid as competitor 
has been introduced to minimize non-specific binding. 
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At the end of SELEX, before sequencing, sequences of the pools were 
cloned with TOPO-TA cloning kit (Invitrogen Life Technologies). 
Afterwards, they were compared by Clustal and their structure predictions 
were obtained by the RNAstructure or DNASIS software. 
Binding and internalization Analysis 
200000 cells were treated with 200 nM of individual aptamers (or the 
starting pool as a negative control) for 30 minutes at 37°C in the presence 
of 100 µg/ml polyinosine used as a nonspecific competitor (Sigma). 
Following two washes with PBS, to remove unbound RNA, bound RNA 
was recovered by TRIzol (Life Technologies) containing 0.5 pmol/ml of a 
non-related aptamer used as a reference control (at each experiment, the 
obtained data were normalized to the reference control). The amount of 
bound RNAs was determined by performing RT-qPCR, as reported, with 
the following primers for the long sequences: P10(Forward):  
5'-TAATACGACTCACTATAGGGAGACAAGAATAAACGCTCAA-
3', P20 (Reverse): 5'-GCCTGTTGTGAGCCTCCTGTCGAA-3', 
Scrambled aptamer and A40s were amplified respectively with the 
following primers Scrambled (Forward): 5'-TTCGTACCGGGTAGG-3’, 
Scrambled (Reverse): 5’-TGACACGTTCTATGTGCA-3’, A40s 
(Forward): 5’-CATCCCTGTTGTTCG-3’, A40s (Reverse) 5’-
CAGGCCTGTTGTGAC-3’.To check internalization, cell surface bound 
aptamers were removed washing three times the cells before recovering 
with cold PBS 0.5M NaCl, and internalization rate was expressed as 
percentage of internalized aptamer compared to total bound aptamer. 
Western blot analysis  
After washing cells twice in ice-cold PBS, protein extracts were prepared 
by incubating cell pellets in JS buffer (50 mM HEPES pH 7.5 containing 
150 mM NaCl, 1% Glycerol, 1% Triton X100, 1.5mM MgCl2, 5mM 
EGTA, 1 mM Na3VO4, and 1X protease inhibitor cocktail). Protein 
concentrations was determined by Bio-Rad Protein Assay reagent, and 
equal amounts of proteins were separated by SDS-PAGE (10% 
polyacrylamide gel). The separated proteins were transferred to 
nitrocellulose membranes (Millipore, Bedford, MA). Membranes were 
blocked for 1 hr with 5% non-fat dry milk in Tris Buffered Saline (TBS) 
containing 0.1% Tween-20. Primary antibodies were incubated at 4°C 
over night, peroxidase-conjugated secondary antibodies were used to 
perform an enhanced chemiluminescence (ECL Star, Euroclone Milan, 
Italy) reaction according to the manufacturer’s protocol in order to 
identify target proteins. Primary antibodies used were: anti-β3tubulin, 
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anti-GFAP, anti- Sox2 (Santa Cruz Biotechnologies, MA), anti-βactin 
(Sigma, Milan Italy). 
 
In vitro limiting dilution assay 
A number of 1, 5 or 10 cells per well were seeded in stem cell medium 
into a 96-well plate. Two weeks after seeding, the number of wells 
containing spheroids for each cell plating density was counted, and 
Extreme limiting dilution analysis was performed using software 
available at http://bioinf.wehi.edu.au/software/elda. Given the long period 
of treatment, aptamers were renewed in wells two times a week at a 
concentration of 100nM. 
 
Cell viability 
Dissociated tumor spheres were counted and 1 × 105 cells/point were 
pretreated with the aptamer or the starting pool, as a negative control, at a 
concentration of 400nM. Following 72 h, cells were seeded 
(1 × 103 cells/well in 96-well plates) and treated with the aptamer or the 
starting pool at 400nM. For long treatments, aptamers were renewed two 
times a week at 100nM. Cell viability was assessed by using CellTiter 
96H AQueous One Solution Cell Proliferation Assay (Promega, Madison, 
WI) measuring the absorbance at 492 nm with Multiskan FC Microplate 
Photometer (Thermo Fischer Scientific). 
 
Transwell migration assay 
Dissociated tumour spheres were counted and 1.5 × 105 cells/point were 
pretreated with the aptamer or the starting pool, as a negative control, at 
400nM. Following 72 h, 1 × 105 cells were seeded in the upper chamber 
of transwell (Corning, Corning, NY, USA) in serum-free DMEM-F12. 
10% FBS was used to induce cells migration towards the transwell lower 
chamber. Migrated cells were visualized after 24 h after seeding by 
staining with 0.1% crystal violet in 25% methanol. The percentage of 
migrated cells was evaluated by eluting crystal violet with 1% sodium 
dodecyl sulfate (SDS) and reading the absorbance at 594 nm wavelength. 
 
RNA extraction and real-time PCR 
After treating cells with aptamers or chimera, total RNAs (miRNA and 
mRNA) were extracted using EuroGOLDTriFast (EuroClone, Milan, 
Italy) according to the manufacturer's protocol. All the RNAs was reverse 
trascribed as described by Iaboni et al72.  Therefore, reverse transcription 
of total mRNA was performed starting from equal amounts of total 
RNA/sample (500 ng) using SuperScript® III Reverse Transcriptase 
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(Invitrogen, Milan, Italy). By contrast, reverse transcription of total 
miRNA was performed starting from equal amounts of total RNA/sample 
(500 ng) using miScript reverse Transcription Kit (Qiagen, Hilden, 
Germany). Quantitative analyses of GFAP, NANOG and β-ACTIN (as an 
internal reference) were performed by real-time PCR using specific 
primers (IDT, Bologna, Italy) and iQTM SYBR Green Supermix (Bio-
Rad).  Quantitative analysis of miRNAs and RNU6B (as an internal 
reference) was performed by real-time PCR using specific primers 
(Qiagen) and miScript SYBR Green PCR Kit (Qiagen). All reactions 
were run in duplicate. To amplify genes of interest we used the following 
primers: 
β-ACTIN fw:5′-TGCGTGACATTAAGGAGAAG-3′, β-ACTIN rv:5′-
GCTCGTAGCTCTTCTCCA-3′; 
NANOG fw:5′-CAAAGGCAAACAACCCACTT-3′, NANOG rv:5′-
TCTGGAACCAGGTCTTCACC-3′; GFAP fw: 5’-
CTGCGGCTCGATCAACTCA-3’; GFAP rv: 
TCCAGCGACTCAATCTTCCTC-3’. 
 
Immunofluorescence analysis 
For immunofluorescence, cells were treated with 500nM Alexa488-A40s 
or Alexa488-unrelated aptamer (Scrambled) at 37°C. Subsequently, cells 
were washed two times with phosphate buffered saline (PBS) and they 
were forced to adhere on glass polylysine coated coverslips for 15 
minutes, then cells were fixed with 4% paraformaldehyde in PBS for 20 
minutes at room temperature. Coverslips were washed three times in PBS, 
mounted with Invitrogen Gold antifade reagent with DAPI and finally 
cells were visualized by confocal microscopy. Images were captured at 
the same setting enabling direct comparison of staining patterns. 
 
Aptamer-miRNA chimera 
For the chimera production, we used RNAs synthesized by TriLink 
Biotechnologies (San Diego, CA). Below, we provide sequences used for 
chimera conjugate: 
miR-34c passenger strand sticky: 5′  
miR-34c guide strand: 5′ 
A40s sticky: 5′ 
All RNAs have 2′-fluoropyrimidine and UU in bold are 3′-overhang.  
To prove that miR-34c is selectively delivered through the aptamer, the 
negative control is made up of the singles portions of the chimera not 
annealated (miR-34c guide strand, miR-34c passenger strand sticky and 
not sticky A40s).  
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To prepare A40s/miR-34c, 10 µM of passenger RNA strand and 10 µM 
of the guide strand, in the appropriate binding buffer 10x (200 mM N-2-
Hydroxyethylpiperazine-N'-2-Ethanesulfonic Acid, pH 7.4, 1.5 M NaCl, 
20 mM CaCl2) were firstly denatured at 95 °C for 15 minutes, 
subsequently brought at 55 °C for 10 minutes and finally warmed up to 37 
°C for 20 minutes. The annealed passenger and guide strand therefore 
obtained, is lastly combined whit A40s sticky and kept 30 minutes at 37 
°C. 
In vivo experiments  
Housed athymic CD-1 nude mice (nu/nu) in a highly controlled 
microbiological environment, were injected subcutaneously with 2 x 106 
BTSC #1-GFP on both flaks. To assess the A40s ability to inhibit in vivo 
tumor growth, mice were intravenously treated by caudal vein with 1,600 
pmol in 100 µl/injection of A40s or unrelated aptamer (named 
scrambled), one injection a week. Tumor growth was measured with 
calipers, tumor volume was calculated as follows: L*(W^2)*3,14/6 (W is 
the shortest dimension and L is the longest dimension). Animals were 
sacrificed following 11 weeks of treatment. 
 
Histology and immuno-immunohistochemistry 
Xenograft formalin fixed tissue were embedded in paraffin block and 
were cut in sections of 5um thickness. The human KI67 (Antigen clone 
MIB-1 IR62; Dako UK Ltd.)  Staining was performed with an automatic 
Benchmark XT staining machine (Ventana Medical Systems Inc.,Tucson, 
AZ, USA) according to manufacture procedure. KI67 nuclear staining 
intensity was evaluated by one expert pathologist. For H&E staining, 2.5 
µm sections of all fixed samples were mounted on superfrost slides and 
performed using standard methodology. 
 
Statistical analysis 
Continuous variables are given as mean ± 1 standard deviation. Statistical 
values were defined using GraphPad Prism 6 (San Diego, CA, USA) 
software, by student’s t-test (two variables) or one-way ANOVA (more 
than two variables). P value < 0.05 was considered significant for all 
analyses. 
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8. Results 
 
8.1. Results of SELEX selection 
 
 In order to identify new specific ligands able to affect glioblastoma 
malignancy, we aimed to isolate aptamers able to distinguish within the 
tumor mass the rare population of glioma cells growing as stem-like non-
adherent spheres.  
To this end, we used a differential cell SELEX approach using primary 
glioma stem cell lines derived from two patients (Fig.7). The line BTSC 
#1 was derived from a patient with a diagnosis of “neuronal 
glioblastoma”, the line BTSC #83 from a patient with a diagnosis of 
“mesenchymal glioblastoma”. 
Cell were propagated as non-adherent spheres in minimal F12 medium 
supplemented with growth factors (epidermal growth factor and basic 
fibroblast growth factor) as previously described (Pallini R. et al.) and 
used as targets in the SELEX process. Stem phenotype was evaluated by 
assessing major stem cells markers (Fig. 8).  
In order to select sequences exclusively able to recognize GSCs and 
discriminate them from differentiated glioblastoma cells, at each round, 
the selection was preceded by one (or two) counterselection step 
incubating the pool with adherent cells obtained from either BTSC.1 or 
BTSC.83 (Table 1).  
 
Figure 7. Schematic representation of Cell-SELEX methodology. 16 rounds of 
selection/counter selection were performed using GSCs or differentiated cells 
respectively, Cells were obtained from patient affected by glioblastoma undergoing 
craniotomy. 
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On the contrary, for counterselections, BTSC.1 or BTSC.83 cell lines 
were grown as adherent cells on matrigel substrate for two weeks in rich 
F12 medium in order to produce the differentiated counterparts (Fig 8).   
 
 
Figure 8. Growth pattern of glioblastoma cultures established under different cell 
conditions. a) Pictures show primary glioblastoma cells growing as suspension or 
adherent cell culture. b) WB illustrates different expression markers between stem cell 
cultures and adherent cell cultures obtained after two weeks of growth in 10% FBS 
media.   
 
 
For selection steps, spheres have been dissociated and then incubated with 
the aptamer pool. Then, in order to eliminate non-selective aptamers, as 
mentioned previously, each selection step was preceded by one or, in the 
last cycles, two counterselection steps incubating the pool with adherent 
cells from either BTSC #1 or BTSC #83. As shown in Table, to 
progressively raise the SELEX selective pressure, we increased number 
of counterselections or of washings and decreased incubation time; 
moreover, we introduced the presence of a competitor to minimize non-
specific binding. 
 
a b 
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Table 5. Schematic presentation of selective approach of cell-SELEX to identify 
specific aptamer ligands for GSCs. Number of selection or counterselection, 
temperature and time of incubation, washes and presence of the competitor are shown 
for each SELEX round. 
 
 
Upon sixteen SELEX rounds, 100 clones were sequenced and aligned for 
homology within their variable core region (Fig.9). Together three 
families dominated the pool with approximately 30% of sequences.  
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Figure 9. Aptamer sequence alignments. The random regions of all the sequenced 
aptamers were aligned using Clustal program. Dendogram shows visual classification of 
similarity among 100 individual sequences cloned after 16 rounds of selection. 
 
In order to validate the information obtained by clustering, the enriched 
pools from rounds 10, 11, 13, 14, 15 and 16 were sequenced by HTS 
(Fig.10).  
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Figure 10. Deep sequencing of last SELEX rounds. The enriched pools from rounds 
10, 11, 13, 14, 15 and 16 were sequenced by high-throughput sequencing (HTS). 
 
As shown, the most enriched sequences identified by HTS belong to the 
four large clusters also found by conventional sequencing (Sanger). 
Indeed, based on the advantages provided by each technique the 
information obtained by coupling the two sequencing approaches may 
provide a reliable way to focus on the most promising sequences. 
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8.2. Binding assay 
 
 Given the good correlation between the two sequencing approaches, we 
determined the sequences that preferentially bind the GSCs tumor spheres 
as compared to cells induced to differentiate growing on adherent 
substrate. To this end, we analyzed by RT-qPCR binding at 200nM on the 
primary cell line BTSC1, the cell line used for the majority of selection 
rounds.  
Analysis has been first performed for those aptamers that belong to the 
major clusters or that are rapidly enriched through the last six SELEX 
rounds, i.e. aptamer Sg. 7, 37, 40L, 89, 92, 38, (Fig. 11a). Sequences 
Sg.5, 37, 40L, 89, 92, showing binding to BTSC1 stem cells, specifically 
recognizes stem cells as shown by poor binding to the differentiated 
counterpart (Fig. 11b). 
 
Figure 11. Binding of the enriched sequences. Binding was performed at 200nM on 
BTSC#1 (a) and adherent cells from the same patient (b); results are expressed relative 
to the background binding detected with the starting pool of sequences used for 
selection. Vertical bars indicate standard deviation values. 
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We then focused on one aptamer, 40L that was the more rapidly enriched 
during the SELEX rounds (at round 10). By RT-qPCR we first validated 
the binding of 40L on a broader set of patient’s derived BTSC. We 
determined at 200 nM the relative binding on nine different primary cell 
lines (#1; 74; 23p; 83;169; 7; 163; 144p; 196). As shown in the panel a of 
Figure 12, 40L may bind to almost all the patients analyzed. Moreover, 
40L shows no detectable binding for the differentiated counterparts of any 
cell lines (Fig. 12). This proved once again, over a larger number of 
patient lines, aptamer ability to selectively bind to GSCs and discriminate 
against differentiated cells obtained from the same patients. 
 
Figure 12. Binding of 40L aptamer to several GBM stem cell lines. Binding was 
performed at 200nM on several GBM cell lines obtained from patients undergoing 
craniotomy. Cells grew up in suspension (a) or adherent condition (b). Results are 
expressed relative to the background binding detected with the starting pool of 
sequences used for selection. In (a) and (b) vertical bars indicate standard deviation 
values. 
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We also tested 40L binding to the stem-like cells obtained from the GBM 
stable cell line U251MG and U87MG. As shown, 40L was able to bind 
only to U251 stem-like cells but not the adherent counterpart (Fig 13a). 
The 40L did not bind U87 stem-like cells (Fig 13b).   
 
 
Figure 13. Binding of 40L aptamer to human glioma cell lines U251 and U87.  a) 
RT-qPCR shows 40L binding on human glioma cell line U251 in suspension and 
adherent conditions. b) RT-qPCR illustrates 40L binding to U87 stem-like cell line. 
Results are expressed relative to the background binding detected with the starting pool 
of sequences used for selection. In (a) and (b) vertical bars indicate standard deviation 
values. 
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8.3. 40L in vitro functional inhibition 
 
Considering that aptamer ability to bind specifically stem cells could 
affect crucial pathways that control stemness state, with the aim of 
determining the functional effects of aptamer binding to BTSCs, we 
decided to investigate the role of 40L on stemness regulation. In this 
respect, we performed a limiting dilution assay (LDA) in #83 primary 
stem cells. This assay is able to establish the frequency of cells having a 
particular function (in our case we focused on the stemness property) that 
are present in a mixed population of cells. 
Data were analyzed using ELDA (Extreme Limiting Dilution Analysis) 
software. Cells were treated with 40L for 2 weeks showed an inhibition of 
spheroid frequency, compared to scrambled aptamer control (Figure 14).  
 
 
 
Figure 14. Reduction of stem cell frequency resulting from 40L binding to BTSC. 
LDA revealed a depletion of stem-like population in BTSC#83 after 40L treatment. 
Cells were treated with the aptamer and limiting dilution analyses were performed using 
Extreme Limiting Dilution Analysis (http://bioinf.wehi.edu.au/software/elda). Results 
are expressed in relation to the background effect detected by using G0, the starting pool 
of sequences employed during the SELEX. P value <0.05 is considered as statistically 
significant. 
 
 
We also evaluated stem/differentiation markers expression following 40L 
incubation. As shown in figure 15, 40L is able to both increase GFAP, 
which is a differentiation marker in brain, and reduce one the 
transcription factor involved with self-renewal and essential in stemness 
maintaining, NANOG, in the two patient cell lines under investigation. 
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This finding underlined that aptamer can afflict both stem cell number 
and stemness state, reducing in this manner the malignancy of tumor. 
 
  
 
Figure 15. 40L reduces stemness increasing differentiation of patients BTSC. Real-
time PCR was performed to analyze GFAP and NANOG levels in BTSC#1 (a) and 
BTSC#83 (b). Results are expressed in relation to the background effect detected by 
using G0, the starting pool of sequences employed during the SELEX. In (a) and (b) 
vertical bars indicate standard deviation values. P value <0.05 is considered as 
statistically significant. 
 
 
 
Further, as determined by MTT analysis 40L aptamer inhibits stem cell 
proliferation of about 50% at 6 days of treatment (Fig. 16a) indicating 
that 40L has also an inhibitory effect on cell vitality.  
 
Figure 16.  40L affects BTSC viability and migration. Panels show cell viability 
reduction (a) and a decrease of cell ability to migrate (b). Results are expressed in 
relation to the background effect detected by using G0, the starting pool of sequences 
employed during the SELEX. In (a) and (b) vertical bars indicate standard deviation 
values. P value <0.05 is considered as statistically significant. 
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Moreover, by using a Boyden-chamber cell migration assay we assessed 
that 40L also interferes with the ability to migrate toward 10% FBS used 
as chemoattractant (Fig. 16b). Same results were obtained with stem cells 
derived from U251 cells (Fig. 17). The capability of 40L to reduce the 
migration can be considered as an interesting potential therapeutic 
function of 40L, since CSCs are now considered as the key element for 
tumor invasion and dissemination. 
 
 
Figure 17.  40L reduces U251 migration. A reduction of cell migration has been seen 
treating U251 cells with 40L.  Results are expressed in relation to the background effect 
detected by using G0, the starting pool of sequences employed during the SELEX. 
 
 
Thus, we assessed that 40L can not only bind GSCs, but also inhibits 
several features that characterized cancer stem cells, the force drive of 
tumor. 
 
 
8.4. Cell uptake efficiency 
 
As previously reported, aptamer sequences for transmembrane cell 
surface receptors may be internalized together with the target protein. 
Thus, we determined if treating BSTC #1 and BSTC #83 cells with the 
40L aptamer would result in rapid internalization. To this end, upon 30 
min of binding, we treated the cells with acid wash to dissociate aptamers 
exposed on the cell surface and then extracted RNA. As determined by 
RT-qPCR, approximately 40% of total bound aptamer was recovered in 
the intracellular compartment of both GSCs (Fig. 18). 
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Figure 18.  Internalization assay of 40L. 40L ability to be internalized into GSC is 
shown. Results are expressed as percentage of the total bound after 30 minutes of 
incubation. Vertical bars indicate standard deviation values. 
 
 
8.5. Modification of the aptamer sequence 
In order to obtain a shorter aptamer with best properties, such as a best 
tissue penetration and a considerable cost reduction, which, at the same 
time, shows comparable characteristics compared to the longer aptamer, 
we utilized a rational approach given by structure nucleic acid prediction 
programs (RNA structure and DNAasis) to design and then synthesize a 
30bp sequence A40s, which represents the truncated version of 40L (fig. 
19).   
 
 
Figure 19. 40L sequence post-SELEX modification. 40L has been cut in order to have 
a shorter aptamer with best properties. Tridimensional shape prediction has been 
illustrated. The selected portion is shown in the red square. 
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After confirming that, A40s maintains the same tridimensional structure 
that this portion has in the long aptamer before cutting, A40s aptamer was 
tested for its ability to bind to BTSC. It showed to contain the active site 
of 40L since it preserves high binding affinity to GSCs.  
Moreover, when it is compared to the negative control, A40s exclusively 
bind to BTSC (Fig. 20a) but not its differentiated counterpart (Fig. 20b) 
as well as 40L aptamer.  
 
 
Figure 20. A40s binding ability. Binding assay was performed at 200nM on #83 cells 
grown as stem (a) or differentiated (b) cells. Results are expressed relative to the 
background binding detected with an unrelated aptamer of the same A40s length. In (a) 
and (b) vertical bars indicate standard deviation values. 
 
In addition, we assessed A40s ability to be internalized into BTSC. As 
shown in figure 21, upon 30 min of incubation, almost 100% of the A40s 
aptamer is internalized into the cells. This suggests that A40s, compared 
to 40L, not only keeps the ability to bind to and discriminate GSCs, but it 
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presents also a higher skill to be internalized after binding.  This ability 
confers to A40s the possibility to be used as therapeutic not only thanks to 
its functional aspects, but also and above all thanks to the opportunity to 
use it as a selective drug delivery system for GSCs. 
 
Figure 21. Internalization assay of A40s. A40s ability to be internalized into GSC is 
shown. Results are expressed as percentage of the total bound after 30 minutes of 
incubation. Vertical bars indicate standard deviation values. 
 
A40s ability to bind BTSC is also assessed and confirmed through 
immunofluorescent assay. As shown in figure 22, Alexa488 labeled A40s 
is more capable to bind to #83 stem cells and to be internalized into them, 
compared to Alexa488 labeled unrelated aptamer (Scrambled) after 30 
minutes of treatment. 
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Figure 22. A40s-Alexa488 binding ability. Immunofluorescence assay was performed 
by treating #83 stem cells with A40s-Alexa488 or Scrambled-Alexa488 at 500nM for 30 
minutes. All images were captured at the same setting enabling direct comparison of 
staining patterns.   
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8.6. A40s in vitro functional aspects  
 
To assess whether A40s is able to maintain an active functionality likened 
to 40L, we evaluated the efficacy of A40s to reduce colony formation by 
limiting dilution assay, as described. Interestingly, as for the longer 
aptamer, A40s was able to reduce stem cells frequency of about 50% 
(Fig. 23). This indicates that A40s still preserves the functional aspect on 
stemness that Sg40 has. 
 
 
Figure 23.  Reduction of stem cell frequency in GSC by using A40s. LDA revealed a 
depletion of stem-like population both in BTSC#1 (a) and in BTSC#83 (b) after A40s 
treatment. Cells were treated with the aptamer and limiting dilution analyses were 
performed using Extreme Limiting Dilution Analysis 
(http://bioinf.wehi.edu.au/software/elda). Results are expressed in relation to the 
background effect detected by using an unrelated aptamer of the same A40s length. P 
value <0.05 is considered as statistically significant.  
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We also assessed stem cells/differentiation markers expression upon 
A40S incubation on BTSC #83. As shown in figure 24, A40s preserves 
40L ability to downregulate NANOG and up-regulate the differentiation 
markers GFAP (Fig 24) compared to negative control. 
 
Figure 24. A40s reduces stemness increasing differentiation in GSC. Real-time PCR 
was performed to analyze GFAP and NANOG levels in BTSC#1 and BTSC#83. Results 
are expressed in relation to the background effect detected by using an unrelated aptamer 
of the same A40s length. Vertical bars indicate standard deviation values. P value <0.05 
is considered as statistically significant. 
 
 
8.7. Design and folding of an aptamer-miRNA conjugate  
 
Since A40s has the ability to be internalized, it can be considered as a 
good candidate for the delivering of molecule able to repress stemness 
properties. For this reason, we wanted to generate, via stick-end 
annealing, a molecular chimera, consisting of a duplex miRNA cargo and 
a nucleic acid aptamer as delivery carrier. Our laboratory acquired much 
experience with aptamer annealings and miRNAs studies. A chimera 
conjugate, between Gl21.T aptamer and miR-34c has already been 
generated in our laboratory. Therefore, we decided to generate a similar 
conjugate by annealing A40s with miR-34c. We fused the passenger 
strand of miR-34c and A40s by the mean of complementary sticky ends 
elongated at the 3’ end of the aptamer and at the 3’ end of the miRNA 
passenger strand, respectively. Finally, we annealed the guide strand of 
miRNA to the template (Fig. 25). We verified the correct annealing of the 
conjugate by non-denaturating gel electrophoresis analysis (data not 
shown).  
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Figure 25. Design and folding of an aptamer-miRNA conjugate. A chimeric 
molecule has been generated by annealing A40s with miR-34c.  
 
 
In order to investigate whether A40s aptamer acts as a selective carrier for 
delivering the conjugated miRNA, we performed in vitro experiments in 
BTSC #83 or differentiated cells treated with A40s/miR-34c for 24-48 
hours. As shown in figure 27, A40s/miR-34c conjugate increased miR-
34c levels; it was assessed by RT-qPCR and it occurred only in BTSC, 
but not in differentiated cells (Fig. 26).  
 
 
 
Figure 26. miR-34c is delivered through A40s only in stem cells. Relative miR-34c 
levels were assessed by using qRT-PCR at 24 and 48h after chimera A40s/miR-34c 
treatment. Chimera ability to deliver miR-34c was evaluated both in stem and in 
differentiated brain tumour cells. 
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8.8. A40s serum stability and in vivo functional aspects 
 
An important feature for the potential clinical translation of new 
therapeutics is represented by their in vivo stability. Therefore, we 
evaluated the A40s stability incubating the aptamer in high concentrated 
human serum solution for increasing times up to one week. Serum-RNA 
samples were recovered at the indicated time-points and analyzed by non-
denaturing polyacrylamide gel electrophoresis (Fig. 27a). As shown, the 
aptamer was stable up to approximately 4-8 hours and then gradually 
degraded. This period of stability seems to be comfortable to reach the 
tumour mass, given that A40s needs only 30 minutes to bind and be 
internalized into the cells. 
After confirming A40s sufficient stability in human serum, we tested in 
vivo effects of A40s by xenografts experiment with BTSC#1 by 
intravenous injection of 1600 picomoles of A40s or scrambled control 
aptamer. As shown in figure 27b, A40s induced a reduction of tumor 
growth strongly affecting tumor size. This is corroborated by histological 
analysis of tumour samples (Fig. 27c) showing a decrease of cell 
positivity to the proliferation marker Ki-67.  
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Figure 27. A40s effect in vivo. a) Non-denaturing polyacrylamide gel electrophoresis 
illustrates A40s stability in 90% serum. b) In vivo experiment was performed to asses 
A40s ability to reach and reduce tumour size. Tumour size is strongly reduces after A40s 
intravenous injection. The arrow indicates treatment initiation. c) Immuno-
histochemistry analysis shows Ki-67 and H&E staining of superfrost slides using 
standard methodology. Results are expressed in relation to the background effect 
detected by using an unrelated aptamer of the same A40s length. 
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9. Discussion  
 
Glioblastoma (formerly glioblastoma multiforme; GBM) is the most 
common primary brain tumour of adulthood and it is the most aggressive 
form of glioma and corresponding to grade IV based on WHO 
Classification. Glioblastoma multiforme, especially the primary form, 
grows very fast within 3 months, and has a very high rate of recurrence. 
Given the high capacity to invade normal brain tissue, GBM is still 
particularly difficult to be completely surgically removed. The median 
overall survival of patients is very low, standing at around 15 months. 
Unlikely, despite many studies aimed to improve treatment efficacy, the 
overall survival has not increased in a significant way in the last years. 
This poor prognosis is strongly caused by the almost universal recurrence 
of glioblastoma tumour. Thus, recurrences seem to be inevitable event for 
GBM patients showing up within 6-9 months after treatment. Sadly, until 
today, there is not any cure for GBM. Thus, the treatment can only affect 
symptomatic aspects which aim to increase the survival rate and 
simultaneously to improve quality of life. 
Glioblastoma Stem Cells appear to be closely involved in tumour 
recurrence. Survey after survey shows that tumours contain a small 
population of cells, named cancer stem cells (CSCs), which is responsible 
for tumor initiation, growth, and recurrence and is liable for cancer 
chemotherapy resistance. Thus, cancer is now recognized as a 
heterogeneous group of cells showing several differentiation phenotypes. 
GBM, as well, is a heterogeneous tumour, consisting of normal cells and 
a small population of CSCs; thus, it is clear how important it is to target 
GSCs in order to increase GBM patient overall survival. Therefore, 
identifying a selective therapy against GSCs is of the utmost importance 
in the fight against GBM. It can be strongly assumed that a specific 
therapy against GSCs can considerably reduce GBM recurrence with an 
impressive prolonged patient survival.  
Aptamers are short, single-stranded oligonucleotides that are high affinity 
ligands for disease-associated proteins expressed on the cell surface. 
Aptamers, as such, appear as excellent candidates able to bind a specific 
target on GSCs cell surface. Moreover, their characteristics (e.g. short 
development and synthesis time, high stability and shelf life, low size and 
cost, ease to be modified, good tissue penetration and high affinity and 
specificity) make aptamers a new class of therapeutic and diagnostic 
molecules comparable or even better then monoclonal antibodies73. 
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Furthermore, the aptamer-mediated targeted delivery of therapeutics has 
been proven many times and, nowadays, many studies have shown the 
great aptamers ability to be internalized when conjugated with other 
molecules74. Consequently, their capacity to be used as a drug delivery 
system has been demonstrated in several occasions75.  
Accordingly, the present work has focused on the identification of 
selective aptamer ligands for glioblastoma stem cells usable as new 
therapeutic tools for glioblastoma. Currently, many are the aptamers 
approved or under examination during clinical trials, Macugen® is the 
first aptamers approved by FDA for age-related macular degeneration 
therapy58. As mentioned, above, two aptamers are already in clinical trials 
to treat cancer.  Here, we took advantage of a panel of primary cultures of 
GSCs isolated from human patient’s tumours to select 40L, starting from 
a library pool. We chose to use primary cells in order to obtain data that 
was more related to the “physiological/pathological condition”. For the 
same purpose, cell-SELEX approach was preferred to protein-SELEX 
technique. 40L aptamer had shown its effectiveness to selectively bind to 
GSCs, discriminating them from the differentiated adherent counterparts. 
Interestingly, 40L not only exclusively binds to GSCs, but it also exhibits 
a functionally activity on target cells. Indeed, it is able to reduce 
stemness, cell viability and migration, explicating the role as stemness 
regulator. 
In order to improve the potential use of this aptamer as therapeutic 
molecule for glioblastoma treatment, we decided to reduce 40L structure 
obtaining a shorter form, able to bind GSCs as well as the longer 40L. 
This reduction has important clinical and economic consequences because 
it can strongly reduce manufacturing costs and improve aptamer tissue 
penetration. 
We found that, similar to 40L, A40s is able to discriminate between GSCs 
and differentiated glioma cells and moreover, it remains functionally 
active on stemness.  
40L and A40s demonstrated to have a high rate of penetration into the 
cells; thus, all their functions can be improved by creating chimeric 
molecules, conjugating 40L or A40s with cell toxic components which 
can be selectively delivered into the target cells trough the aptamer. 
Moreover, the aptamer on its own has proved to be capable of affecting in 
vivo proliferation of GSCs. Indeed, in vivo experiment shows a very 
encouraging result with a good reduction of the tumour volume. 
Both aptamers proved to be able to affect cell stemness features, but 
unfortunately, much needs to be done to understand the mechanism by 
which it happens. Moreover, the aptamer target is still unidentified as well 
65 
 
as its affinity for the target which remains undefined at this stage. For this 
reason, elucidation of pathway, which is governed by aptamer action, can 
improve aptamer potential application in glioblastoma therapy. Thus, 
other aspects still have to be investigated.  
Future therapeutic approach, which targets key pathways regulating the 
stemness state of glioma stem cells, is a rapidly emerging request for 
glioblastoma treatment. Therefore, targeting the stemness-like properties 
of cancer cells with aptamers as A40s may represent a promising strategy 
for cancer therapy in the future. Considering that A40s is able to modify 
stemness properties, its use in therapy could strongly contribute to reduce 
the GSCs number and to increase their sensitization to chemotherapy, 
greatly impeding tumor relapse and metastasis.  
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10. Conclusion 
In this work, we identified and characterized a new tool to target glioblastoma 
stem cells. We described the potential use of aptamer 40L (and A40s) as a 
therapeutic molecule able to selectively bind GBM stem cells and 
discriminate them from differentiated cells.  
Despite the aspects which have yet to be considered, such as target 
identification, it can be easily concluded that 40L is able to reduce 
viability, migration and stemness. Likewise, A40s, the truncated form of 
40L, is able to bind exclusively to GSCs, distinguishing GBM stem cells 
from differentiated cells, and it too is capable of reducing stemness. 
Furthermore, both the aptamers, especially A40s, can be easily 
internalized into target cells. This confers the additional opportunity to 
use them as drug delivery system. 
In addition, in vivo experiment using A40s has been proved its ability to 
reduce GBM stem cells proliferation by decreasing tumor size in mice, 
showing a very encouraging result.  
In summary, 40L and A40s demonstrate to be, at least potentially, a very 
useful tool in the GBM treatment, being able to selectively act on GSCs 
on which currently therapies fail. 
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